Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[ash111]

Kitov,might go 1000%+ till year-end imo,i did tons of DD here.this is the only bio that completed P3 and no more additional tests will be needed.Because the trial target was fully achieved, there is no need to recruit additional patients, and the trial results have been declared final.CAP IS ONLY $12M. I think BIG PHARM will be falling all over themselves to get the rights to distribute this multi BILLION dollar drug..Insiders doubled position since IPO took place 5 mounts ago.

Kitov CEO Isaac Israel said, "KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients' risk of suffering a heart attack or stroke, while also reducing cost for payers…

From 2014 agreement (Kitov/Dexcel):
"In addition, in exchange for a right of first negotiation with regard to future global marketing rights for KIT-302 and for an option to negotiate the future commercial manufacture of KIT-302 Dexcel agreed to pay us $500,000 in two equal installments based on milestones during the development and manufacturing period (of which the first payment of $250,000 was made in May 2015 upon the attainment of the second development milestone)"...
http://www.nasdaq.com/markets/ipos/filing.ashx?filingid=10541185

DD 16-Feb-2016:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120553866

Feb. 29, 2016 "a target range for KTOV of $13 to $29 per share":
http://seekingalpha.com/article/3939596-kitov-pharmaceuticals-bullish-valuation-based-comparables

"the company's drug currently worth $ 80 million",translated,using google translate: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120662272

"Dr. Gregory Slbrg'o analyst believes that the good is "a rare case of health sector" - company presented positive results in the clinical trial phase III Hfibotli and its lead product is a clinically effective and proven mechanism. "Kitov market cap is negligible," writes the analyst. "We believe its leading product, KIT-302, has the potential to reach blockbuster status (multi-selling drug, S.h.o) in the US alone. "
In fact, the analyst estimates that by the year 2023 drug sales will reach 600 million US dollars a year. KIT-302 drug for the treatment of two medical conditions: pain resulting from osteoarthritis and hypertension, a common side effect of antidepressant use pain as a result. the drug is a combination of the active ingredient of Celebrex pain antioxidant (Pfizer's drug, already has its generic versions on the market), and amlodipine besylate, a drug to treat hypertension".
translated (google)- http://www.globes.co.il/news/article.aspx?did=1001104522

Total O/S ("Capital Listed for Trading on TASE"): 77,915,620.
Total ADS, 3,366,974 (KTOV). this is actually the Nasdaq listed shares,they called them "Kitov Nasdaq Listed Warrants" but these are not actually Warrants- Each ADS represents 20 Ordinary Shares of the Company(listed On TASE,Israel).
there are also 157,945 Warrants (KTOVW). Each ADS represents 20 Ordinary Shares of the Company. The aggregate number of Kitov Underwriter Warrant exercise shares is 3,158,900. Even with a fully diluted market cap is about $20m,this is still a killer deal relating market potential of billions.imo.these Warrants can be executed till 2020 and i find no reason to execute the upcoming year due KIT-302 gonna hit the market in 2017 as represented by the company.

updated Registry of Securities Holders of the Company as of March 2, 2016:
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=11230974

Market Cap (03/03/2016),46,827 NIS thousands, is about $12m( 1USD= 3.9 NIS). Capital Listed for Trading
77,915,620 in Israel. http://www.tase.co.il/Eng/general/company/Pages/companyMainData.aspx?companyID=000765&subDataType=0&shareID=00765016

Newest presentation:
http://kitovpharma.investorroom.com/events-and-presentations?item=8